LLY

973.04

-1.5%↓

JNJ

221.62

-0.89%↓

ABBV

202.98

-0.73%↓

UNH

367.52

+0.04%↑

AZN

181.15

-1.71%↓

LLY

973.04

-1.5%↓

JNJ

221.62

-0.89%↓

ABBV

202.98

-0.73%↓

UNH

367.52

+0.04%↑

AZN

181.15

-1.71%↓

LLY

973.04

-1.5%↓

JNJ

221.62

-0.89%↓

ABBV

202.98

-0.73%↓

UNH

367.52

+0.04%↑

AZN

181.15

-1.71%↓

LLY

973.04

-1.5%↓

JNJ

221.62

-0.89%↓

ABBV

202.98

-0.73%↓

UNH

367.52

+0.04%↑

AZN

181.15

-1.71%↓

LLY

973.04

-1.5%↓

JNJ

221.62

-0.89%↓

ABBV

202.98

-0.73%↓

UNH

367.52

+0.04%↑

AZN

181.15

-1.71%↓

Начало・Списък с акции・Rhythm Pharmaceuticals Inc
Search

Rhythm Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

95.03 0.33

Силна покупка

Обновена цена 7.05.2026 г., 16:34 ч. UTC

КупиПродай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

93.4

Максимум

96.79

Ключови измерители

By Trading Economics

Приходи

5.4M

-48M

Продажби

6M

57M

Марж на печалбата

-82.974

Служители

414

EBITDA

5.1M

-43M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+59.36% upside

Дивиденти

By Dow Jones

Следващи печалби

4.08.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-565M

5.9B

Предишно отваряне

94.7

Предишно затваряне

95.03

Настроения в новините

By Acuity

61%

39%

300 / 347 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

60 / 65.58 Подкрепа & съпротива

Rhythm Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.05.2026 г., 23:41 ч. UTC

Печалби

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

DJ

Прочетени

6.05.2026 г., 21:40 ч. UTC

Печалби

Nutrien Logs Higher Profit, Sales Growth in 1Q

DJ

Прочетени

6.05.2026 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

DJ

Прочетени

6.05.2026 г., 23:34 ч. UTC

Пазарно говорене

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

DJ

Прочетени

6.05.2026 г., 23:13 ч. UTC

Печалби

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

DJ

Прочетени

6.05.2026 г., 23:13 ч. UTC

Печалби

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

DJ

Прочетени

6.05.2026 г., 23:12 ч. UTC

Печалби

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

DJ

Прочетени

6.05.2026 г., 23:11 ч. UTC

Печалби

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

DJ

Прочетени

6.05.2026 г., 23:11 ч. UTC

Печалби

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

DJ

Прочетени

6.05.2026 г., 23:11 ч. UTC

Печалби

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

DJ

Прочетени

6.05.2026 г., 23:11 ч. UTC

Печалби

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

DJ

Прочетени

6.05.2026 г., 23:11 ч. UTC

Печалби

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

DJ

Прочетени

6.05.2026 г., 23:11 ч. UTC

Печалби

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

DJ

Прочетени

6.05.2026 г., 23:07 ч. UTC

Печалби

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

DJ

Прочетени

6.05.2026 г., 23:06 ч. UTC

Печалби

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

DJ

Прочетени

6.05.2026 г., 23:06 ч. UTC

Печалби

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

DJ

Прочетени

6.05.2026 г., 23:05 ч. UTC

Печалби

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

DJ

Прочетени

6.05.2026 г., 23:04 ч. UTC

Печалби

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

DJ

Прочетени

6.05.2026 г., 22:50 ч. UTC

Печалби

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

DJ

Прочетени

6.05.2026 г., 22:25 ч. UTC

Пазарно говорене

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

DJ

Прочетени

6.05.2026 г., 22:11 ч. UTC

Печалби

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

DJ

Прочетени

6.05.2026 г., 22:11 ч. UTC

Печалби

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

DJ

Прочетени

6.05.2026 г., 22:05 ч. UTC

Пазарно говорене

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

DJ

Прочетени

6.05.2026 г., 21:58 ч. UTC

Печалби

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

DJ

Прочетени

6.05.2026 г., 21:47 ч. UTC

Пазарно говорене
Печалби

Costco Posts 13% Sales Growth in April -- Market Talk

DJ

Прочетени

6.05.2026 г., 21:46 ч. UTC

Печалби

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

DJ

Прочетени

6.05.2026 г., 21:40 ч. UTC

Печалби

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

DJ

Прочетени

6.05.2026 г., 21:35 ч. UTC

Пазарно говорене

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

DJ

Прочетени

6.05.2026 г., 21:32 ч. UTC

Горещи акции

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

DJ

Прочетени

6.05.2026 г., 21:29 ч. UTC

Печалби

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

DJ

Прочетени

Сравнение с други в отрасъла

Ценова промяна

Rhythm Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

59.36% нагоре

12-месечна прогноза

Среден 136.38 USD  59.36%

Висок 158 USD

Нисък 105 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Rhythm Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

14

Купи

0

Задържане

0

Продай

Според 14 анализатори, дали борсови рейтинги на Rhythm Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

60 / 65.58Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Средносрочен план

Bullish Evidence

All events are bullish.

Дългосрочен план

Bullish Evidence

Recent bullish events outweigh bearish events.

Настроение

By Acuity

300 / 347 Класиране в Здравеопазване

Настроения в новините

Мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Други акции от сектора

LLY

Eli Lilly and Co.

973.04

↓-1.5%

JNJ

Johnson and Johnson

221.62

↓-0.89%

ABBV

AbbVie Inc

202.98

↓-0.73%

UNH

UnitedHealth Group Inc

367.52

↑ +0.04%

AZN

AstraZeneca PLC

181.15

↓-1.71%
help-icon Live chat